Insomnia

>

The NeurologyLive® Insomnia Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the disorder of sleepiness.

Latest News

Pooled Phase 3 Data Suggests 50 mg Daridorexant as Most Effective Starting Dose in Insomnia
Pooled Phase 3 Data Suggests 50 mg Daridorexant as Most Effective Starting Dose in Insomnia

June 5th 2024

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.

Cognitive Behavioral Therapy for Insomnia Shows Promise in Pilot Trial of Epilepsy
Cognitive Behavioral Therapy for Insomnia Shows Promise in Pilot Trial of Epilepsy

June 3rd 2024

In-hwan Baek, PhD, professor of pharmacy at Kyungsung University
Meta-Analysis Reveals Safety Concerns With FDA-Approved Dual Orexin Receptor Antagonists for Insomnia

March 11th 2024

Paolo Baroldi, MD, PhD, the chief medical officer at Vanda
FDA Issues Complete Response Letter for Vanda Pharmaceuticals' Tasimelteon for Insomnia

March 11th 2024

Michael Perlis, PhD
Key Components Identified for Improving Efficacy of Cognitive Behavioral Therapy in Chronic Insomnia

February 1st 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.